Skip to Main Content

Paper Details

Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.
Pharmacoecon Open
2
2023
Author NameAffiliation
Frances A ShepherdUniversity Health Network, Princess Margaret Cancer Centre and the University of Toronto
Thomas John
  • 1 - 2

Datasets

Release 1.2